Ignite Creation Date:
2024-05-05 @ 5:03 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00374296
Status:
TERMINATED
Last Update Posted:
2015-07-01
First Post:
2006-09-07
Brief Title:
MGCD0103 in Elderly Patients With Previously Untreated AMLHigh Risk MDS or Adults With RelapsedRefractory Disease
Sponsor:
Mirati Therapeutics Inc
Organization:
Mirati Therapeutics Inc
Study Overview
Official Title:
A Phase II Study of MGCD0103 MG-0103 in Patients With Acute Myelogenous LeukemiaHigh Risk MDS Who Are Elderly and Have Previously Untreated Disease or Who Are Adult and Have RelapsedRefractory Disease
Status:
TERMINATED
Status Verified Date:
2015-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The Clinical Development Program for MGCD0103 is being re-evaluated
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this study MGCD0103 a new anticancer drug under investigation is given three times per week to elderly patients with previously untreated acute myelogenous leukemiahigh risk myelodysplastic syndrome or adults with relapsedrefractory disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None